DOI: 10.1093/ibd/izad165 ISSN:
1-Year Comparison of Clinical and Endoscopic Outcomes of Tofacitinib vs Vedolizumab for Ulcerative Colitis After Anti-Tumor Necrosis Factor Failure: A Real-World Cohort Study in the United States
Rahul S Dalal, Puza P Sharma, Kanwal Bains, Jordan C Pruce, Jessica R Allegretti- Gastroenterology
- Immunology and Allergy
In this retrospective cohort study, tofacitinib was associated with higher adjusted odds of steroid-free clinical remission at 52 weeks and endoscopic remission within 52 weeks compared with vedolizumab. Adverse events were consistent with the known safety profiles of these agents.